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Abstract
Background Our ability to guide cells in biomaterials for in
vivo bone repair is limited and requires novel strategies.
Short-interfering RNA (siRNA) allows the regulation of
multiple cellular pathways. Core binding factor alpha 1
(Cbfa1) and hypoxia-inducible factor 1 (HIF-1) pathways
can be modulated to direct bone formation via siRNA against
guanine nucleotide-binding protein alpha-stimulating activity
polypeptide 1 (siGNAS1) and prolyl hydroxylase domain-
containing protein 2 (siPHD2), respectively.
Questions/Purposes We determined whether the admin-
istration of siGNAS1 and siPHD2 in mesenchymal stem
cells (MSCs) promotes osteogenic phenotype, the dose-
dependent effects of siGNAS1 on MSC differentiation to
osteogenic phenotype, and whether the two siRNAs pro-
mote bone formation in vivo.
Methods siRNAs were administered to MSCs at Day 0,
and protein expression of bone-specific markers was
assessed at Days 1, 2, and 4 (n = 3/group/time point). In an
in vivo model using seven sheep, chambers containing silk
fibroin-chitosan (SFCS) scaffolds with siRNA were
implanted over the periosteum and harvested at Days 7, 21,
36, and 70 (n = 4/group/time point, except at Day 70
[n = 2]) to assess bone formation.
Results siGNAS1 promoted collagen I and osteopontin
expression, whereas siPHD2 had no effect in vitro. Dose-
dependent effects of siGNAS1 on ALP expression were
maximal at Day 1 for 10 lg/mL and Day 4 for 100 lg/mL.
In vivo, by Day 70, mean bone volume increased compared
to Day 7 for siGNAS1-SFCS (47.8 versus 1.8 mg/mL) and
siPHD2-SFCS (61.3 versus 1.5 mg/mL).
Conclusions Both siPHD2 and siGNAS1 support bone
regeneration in vivo, whereas only siGNAS1 regulates
bone phenotype in MSCs in vitro.
Clinical Relevance While the use of autologous tissue is
limited for reconstructing critical-sized defects, the devel-
opment of biomaterial-based approaches to promote bone
formation may abrogate some of those limitations.
Introduction
Regenerative medicine has the potential to revolutionize
reconstructive approaches for critical-sized bone defects
by providing prefabricated tissue with patient-specific
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geometry while minimizing donor tissue requirements [4,
13, 17]. Repair of critical-sized bone defects with cadaver-
derived bone graft, biomaterials such as titanium,
hydroxyapatite, and ceramics, autologous vascularized
tissue transfers, or prosthetic rehabilitation have limitations
and thus the use of biodegradable bone-conducting bio-
materials is being explored [13]. Ectopically grafted
periosteum and silk fibroin-chitosan (SFCS) biomaterial
reportedly regenerate bone in an in vivo sheep model [4, 7,
8, 16]. These studies suggest an approach to bone repair by
prefabricating biomaterial-based transferable bone tissue
flaps is a potential alternative.
Stimulation of cellular processes for tissue-engineering
applications has focused primarily on delivery of proteins or
nucleic acids, antisense oligonucleotides, adenoviral-based
delivery, and hammerhead ribozymes, which have been
used to modulate the expression of proteins [6, 10]. These
methods, however, have been plagued with oligonucleotide
stability [10] or nonspecific global suppression [6]. Short-
interfering RNA (siRNA) is a gene-silencing process
involving the introduction of 21- to 25-nucleotide double-
stranded RNA into a cell that results in the degradation of the
complementary mRNA via a multiple enzyme complex
called RNA-induced silencing complex [3]. A short nucle-
otide can be introduced to target multiple pathways/factors,
thus providing a means to guide diverse and interlinked
cellular processes simultaneously [3]. siRNA that targets the
hypoxia pathway turns on the angiogenic protein expression
via the hypoxia-inducible factor 1 (HIF-1) and siRNA that
targets the bone differentiation pathway turns on the core
binding factor alpha 1 (Cbfa1) pathway to activate expres-
sion of bone differentiation proteins.
Cbfa1 is a transcript factor important in differentiation of
bone precursor cells into osteoblasts and subsequent bone
formation. The activity of Cbfa1 is regulated by the a chain
of the heterotrimeric G protein, Gsa, and is transcribed by
the guanine nucleotide-binding protein (G protein) alpha-
stimulating activity polypeptide 1 (GNAS1) gene (Fig. 1A)
[6, 10]. Expression of Gsa inhibits osteogenic differentiation
by means of proteolytic degradation of Cbfa1. The down-
regulation of the GNAS1 gene via siRNA leads to the
increased expression of Cbfa1 that would stimulate the
production of bone-differentiating proteins such as osteo-
pontin, collagen I, and osteocalcin [3, 15].
HIF-1 is a transcription factor and a heterodimer com-
posed of two subunits: HIF-1a and HIF-1b (aryl
hydrocarbon receptor nuclear translocator), whose pathway
is targeted to control angiogenesis via the silencing of prolyl
hydroxylase domain-containing protein 2 (PHD2) (Fig. 1B)
[1, 18]. HIF-1a expression is tightly regulated by oxygen
tension. PHD2 hydroxylates the key proline residues of
HIF-1a, which targets HIF-1a for destruction via the ubiq-
uitin-proteasome pathway, in normoxia. Under hypoxic
conditions, HIF-1a accumulates leading to its stabilization
and it partners with HIF-1b to bind to the HIF response
elements on its target genes to turn on transcription of genes
important to vasculogenesis, such as vascular endothelial
growth factor (VEGF), erythropoietin (EPO), stromal-
derived factor 1 (SDF1), leptin, and inducible nitric oxide
synthase (iNOS) [11, 18]. The siRNA against PHD2 that
blocks the binding of PHD2 with HIF-1a promotes the
expression of angiogenic proteins via the hypoxia pathway.
We hypothesized blocking of the bone differentiation
pathway via siRNA against GNAS1 (siGNAS1) and the
hypoxia pathway via siRNA against PHD2 (siPHD2) would
affect MSC proliferation and expression of collagen,
osteopontin, and alkaline phosphatase (ALP).
We therefore determined (1) whether the administration
of siGNAS1 and siPHD2 in MSCs would promote osteo-
genic phenotype (cell proliferation and collagen,
osteopontin, and ALP expression); (2) the dose-dependent
effects of siGNAS1 on MSC differentiation to osteogenic
phenotype (ALP assay) and the concentration of siGNAS1
needed for the in vivo bone formation study; and
(3) whether the two siRNAs promote the formation of bone
in vivo (bone volume and density with time).
Materials and Methods
This study was designed to investigate bone differentiation
in SFCS scaffolds via the administration of siRNA in
in vitro and in vivo assays (Fig. 2). The effect of siGNAS1
dosage on MSC differentiation to bone phenotype was
determined using ALP assay (n = 3/treatment group/con-
centration/time point). The SFCS scaffolds were embedded
with either a single siRNA or both together and bone
volume and density with time were determined using
micro-CT in an in vivo sheep model (n = 4/treatment
group/time point, except at Day 70 [n = 2]).
For in vitro transfection with siRNA, human MSCs
(ScienCellTM Research Laboratories, Carlsbad, CA, USA)
were maintained in MSC medium, supplemented with 5%
fetal bovine serum, 1% MSC growth supplement, and 1%
penicillin/streptomycin solution. MSCs were incubated at
37 C in a humidified chamber containing 5% CO2. MSCs
were seeded in six-well tissue culture plates at * 333,333
cells/well (n = 3 wells/treatment group). We had three time
points with n = 3/group for cell proliferation, collagen
expression, and osteopontin expression. Thus, there were
12 wells/time point for cell proliferation and 15 wells/time
point for collagen and osteopontin expression. Overall, we
had 36 wells for cell proliferation and 45 wells for collagen
and osteopontin expression. Cells were allowed to adhere
overnight. To transfect the cells with the siRNA, it was mixed
with 5 lL Ambion siPortTM Amine Transfection Agent (Life
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Technologies, Grand Island, NY, USA) and incubated at
room temperature for 10 minutes. Cells seeded in the wells
were transfected with 5 lg/mL siGNAS1 (50-GGCAACCA
AAGUGCAGGACtt-30; Applied Biosystems/Ambion Inc,
Austin, TX, USA), siPHD2 (50-AACGGGTTATGTACGTC
ATGT-30), siGNAS1-siPHD2 (Qiagen Inc, Valencia, CA,
USA), siLamin (50-CUGGACUUCCAGAAGAACAtt-30;
Applied Biosystems/Ambion Inc), or nothing (control) at
Time 0. After incubation for 1, 2, or 4 days, the cells were
ready for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay (cell proliferation), Western blot
analysis (osteopontin), and collagen assay. To count the
Fig. 1A–B (A) A schematic of the Cbfa1 pathway shows the action
of siGNAS1. The blocking of the GNAS1 gene via siGNAS1 results
in the activation of the Cbfa1 pathway and expression of proteins such
as osteopontin, collagen I, and others. GTP = guanosine triphos-
phate; GDR = guanosine diphosphate; cAMP = cyclic adenosine
monophosphate. (B) A schematic shows the hypoxia pathway
regulated by HIF-1 (HIF-1a and HIF-1b) and targeted to regulate
angiogenesis by blocking of PHD2 via siPHD2, which allows the
binding of HIF-1a to HIF-1b and expression of VEGF, EPO, SDF-1,
and iNOS.
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number of cells, we used an MTT assay from BioAssay
Systems (Hayward, CA, USA). The reagents were incubated
for 5 hours and measured by spectrophotometer.
For the osteopontin assay, the cells grown in the six-well
tissue culture plates were lysed at the previously mentioned
time points in 100 lL lysis buffer containing 2.5 lL
A
B
Fig. 2A–B Flow diagrams show
the setup of the (A) in vitro and
(B) in vivo studies. The in vitro
study involved the transfection
of MSCs with siGNAS1 and
siPHD2 and evaluation of cell
proliferation, collagen expres-
sion, osteopontin expression, and
dose-dependent ALP expression.
The in vivo study involved
embedding either siGNAS1 or
siPHD2 or both in SFCS scaf-
folds and implanting them over
periosteum engrafted on the la-
tissimus dorsi muscle to fabricate
ectopic bone.
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phenylmethylsulfonyl fluoride, 2.5 lL sodium orthovan-
date, 2.5 lL protease inhibitor cocktail, and 1455 lL
radioimmunoprecipitation assay buffer (all from Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Briefly, cell
pellets were suspended in lysis buffer and kept on ice for
10 minutes. The suspensions were centrifuged at 4500 rpm
for 10 minutes and supernatants were collected for analy-
sis. Cell lysis aliquots equivalent to 50,000 cells were taken
from each sample, mixed with similar volume of sodium
dodecyl sulfate (SDS) buffer (BioRad, Hercules, CA, USA)
containing 5% b-mercaptoethanol (Sigma-Aldrich Corp,
St Louis, MO, USA), and heated at 100 C for 5 minutes.
Samples were separated on a 10% SDS-polyacrylamide gel
and then blotted for Western analyses. The nitrocellulose
membrane was stained with antibodies specific for osteo-
pontin (Santa Cruz Biotechnology). Intensities of various
bands on Western blot films were scanned and analyzed
using Gel-Pro AnalyzerTM software (Media Cybernetics,
Silver Spring, MD, USA). We normalized the band inten-
sities from all time points to Day 1 control.
We performed the SircolTM Soluble Collagen Assay
(Biocolor Ltd, Carrickfergus, UK) on the siRNA-transfected
MSCs. Absorbance was read at 550 nm using a microwell
plate reader. Measurements were compared to standards and
statistical analyses were performed appropriately.
For the ALP assay, we cultured MSCs in 96-well plates
at 1000 cells/well overnight. siGNAS1 or siLamin at 10,
50, and 100 lg/mL (n = 3 wells/concentration) was added
to 6-mm 75:25 SFCS scaffolds and placed over the MSCs
in the wells. Scaffold only and no scaffold were used as
control wells. We used the TRACP & ALP Assay Kit
(Takara Bio, Inc, Otsu, Japan) to assess ALP in the siRNA-
transfected MSCs. Absorbance was measured at 405 nm
using a microwell plate reader.
Seven adult sheep raised and housed at The University
of Texas M. D. Anderson Cancer Center’s Michael E.
Keeling Center for Comparative Medicine and Research at
Bastrop, TX, USA, were used for the in vivo study. Laws
on animal experimentation were strictly followed and all
protocols involving the animals were preapproved by the
institutional animal care and use committee. Sheep were
anesthetized with diazepam 0.2 mg/kg (intravenously),
ketamine 4 mg/kg (intravenously), and 3% isoflurane
(endotracheal via ventilator). Once the sheep were fully
anesthetized, 0.02 mg/kg succinyl choline chloride was
administered via an intravenous drip during the first
30 minutes of an approximately 90-minute procedure to
reduce the occurrence and intensity of muscular spasms
during surgery. Before surgery, the skin above the animal’s
lateral chest wall was sheared, sterilized using iodine, and
draped. The sheep was given an intramuscular injection of
1.0 g cefazolin and an incision was made overlying and
parallel to the seventh or eighth rib to expose the two
adjacent ribs (Fig. 3). Two pieces of periosteum from each
of the seven sheep were carefully harvested (to avoid
damage to the cambium layer) from the outer table of two
adjacent ribs, each measuring 12 to 15 cm in length and the
entire width of each rib (approximately 1–1.5 cm). The
periosteum was lifted from the rib with a subperiosteal
dissection. Each piece was sectioned into either four or five
segments that were 3 cm long to make a total of nine
pieces. Each segment was then transplanted to the latissi-
mus dorsi with the cambium layer facing up and sutured to
the underlying muscle using 5.0 PROLENE1 polypropyl-
ene suture (Ethicon, Inc, Somerville, NJ, USA).
A total of two sheep in each time point gave the study
85% power to detect an increase in maximal bone volume
for siGNAS1-SFCS from Day 7 to Day 36 and 99% power
from Day 7 to Day 70. It gave 99% power to detect an
increase in maximal bone volume for siGNAS1-SFCS from
Day 7 to Day 70 and Day 21 to Day 70. The study had 97%
and 84% power to detect a siGNAS1-siPHD2-SFCS
increase from Day 7 to Day 70 and Day 36 to Day 70,
respectively.
We fabricated chambers (inner dimensions: 1 9 3 9
1.25 cm3) with polymethylmethacrylate (PMMA) and
glued polydimethyl siloxane (PDMS) to the edges of the
open end of the chamber. PDMS was then used to suture
the chamber to the latissimus dorsi muscle. Chambers
containing SFCS scaffolds with siGNAS1 (n = 4), siPHD2
Fig. 3A–E Photographs illustrate the surgical procedure for the in
vivo sheep surgery. (A) Two pieces of periosteum (12–15 cm; width
approximately 1–1.5 cm) were harvested from sheep ribs using a
scalpel and periosteal elevator dissection, (B) cut into eight to nine
3-cm pieces, and (C) autografted over the latissimus dorsi muscle of
the same sheep at 3 cm apart. (D) PMMA chambers, one chamber
each for pure SFCS scaffold, bone graft, and empty as controls
and two chambers each for siGNAS1-SFCS, siPHD2-SFCS, and
siGNAS1-siPHD2-SFCS, were created and (E) implanted on top of
the grafted periosteum on the latissimus dorsi muscle using PDMS to
suture and 5.0 PROLENE1 suture.
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[2] (n = 4), and siGNAS1-siPHD2 (n = 4) (75:25 blend
[6] with 50 lg/mL of the siRNA) were implanted on top of
the grafted periosteum over the latissimus dorsi muscle
using the PDMS to suture the chamber to the muscle with
5.0 PROLENE1 suture. Each of the seven sheep had nine
chamber implants (two for each of the four experimental
groups and one for each control). Chambers were harvested
after euthanasia (Beuthanasia 0.22 ml/kg intravenously) at
Days 7, 21, and 36 with harvests from two sheep at each
time point. Empty chambers (negative control, n = 2),
chambers filled with bone graft (clinically relevant positive
control, n = 2), and chambers filled with SFCS (n = 2)
were controls for the time points above. Bone chips were
used as fresh bone graft by dissecting bone from the ribs
and crushing in a bone mill (Medtronic, Inc, Fort Worth,
TX, USA). A similar procedure was used for implantation
and harvest at Day 70, although the sample sizes for con-
trols and experimental conditions were n = 1 and n = 2,
respectively, since there was only one sheep harvested. To
assess the extent of vascularization in SFCS scaffold after
bone formation at the time of harvest, the lateral thoracic
artery was perfused with india ink using an intravenous
injection.
At the time of harvest, samples were preserved in 10%
formalin and sent for micro-CT scans and then histologic
staining. We performed micro-CT scans to assess bone
formation in the chambers at the harvest time points at
92-lm sections/slices at the M. D. Anderson Small Animal
Imaging Core facility using a Model RS-9 tabletop CT
scanner (General Electric Medical Systems, London, ON,
Canada). This scanner has a gantry that is rotated by a
servo mechanism around the object bed, imaging the entire
object in one pass. The gantry features a tungsten anode
x-ray source, operated at 80 jVp and 450 iA, which is fixed
opposite a detector composed of a cesium iodide scintil-
lator and a charge-coupled camera. We used GE
Healthcare’s MicroView software (Version 2.2) to analyze
the regenerated bone. Regions of interest were outlined,
three-dimensional isosurface images were generated, and
bone volume and bone mineral densities were calculated
[11]. The threshold was set to 100 for these measurements.
Of the total four samples for the experimental groups and
two samples for the control groups, we selected one image
we believed representative (see below).
Subsequent to micro-CT imaging, samples were
demineralized and dehydrated using a series of ethanol
solutions and embedded in paraffin. Serial sections (4 lm)
were cut, set on glass slides, and baked at 56C overnight.
Different sections from each sample were then deparaffi-
nized, rehydrated, and stained with hematoxylin and eosin
(H&E) or Movat’s pentachrome and imaged with bright-
field light microscopy (Olympus IX50; Olympus America
Inc, Center Valley, PA, USA).
Two-way ANOVA with Bonferroni post hoc test was
conducted to determine the effect of the two siRNAs
(independent variables) by assessing differences in
dependent variables with time (independent variable): cell
number, collagen expression, and osteopontin expression.
Dose (independent variable)-dependent effects on ALP
expression (dependent variable) with time (independent
variable) were assessed using two-way ANOVA with
Bonferroni post hoc test. One-way ANOVA with Tukey
post hoc test was used to assess differences in bone volume
(dependent variable) and bone density (dependent variable)
with time (independent variable) among the siRNA treat-
ment groups (independent variables). Our primary outcome
was the bone volume measured by micro-CT scan. All data
are reported as mean ± standard error of the mean (SEM)
with the number of samples averaged per group (n) given
in parentheses for each condition. We used GraphPad
Prism1 5 (GraphPad Software, La Jolla, CA, USA) to
determine differences in cell proliferation and protein
expression in vitro and bone volume and bone density in
vivo between different groups (type of siRNA) with time.
The sample size for bone volume and bone mass density
measurements at Day 70 for SFCS controls was n = 1 and
was not used for comparisons. We performed post hoc
power analysis to determine the power in the study using
nQuery Advisor1 7.0 (Statistical Solutions, Saugus, MA,
USA).
Results
Cells proliferated from Day 1 to Day 4 with and without
administration of siRNA, although the relative increase in
cell number by Day 4 for cells with no siRNA was higher
than for cells with siGNAS1 or siPHD2 or siGNAS1-
siPHD2 (Fig. 4). For siGNAS1-administered MSCs, col-
lagen I synthesis increased by Day 2 and then decreased by
Day 4 (Fig. 5) as the siRNA was depleted. Osteopontin
expression was maximal for siGNAS1-administered cells
at Day 1 and was higher than that in cells administered
siPHD2, siGNAS1-siPHD2, or siLamin (Fig. 6).
At Day 1, cells administered with 100 lg/mL siGNAS1
had lower ALP expression than the cells administered 10
and 50 lg/mL siGNAS1 (Fig. 7). ALP expression was
higher for cells treated with siGNAS1 at concentrations of
10 and 50 lg/mL siGNAS1 on Day 1 as compared to
untreated cells cultured on petri dishes with no scaffold and
no siGNAS1. The presence of scaffold increased the ALP
expression compared to no-scaffold controls, with no
siGNAS1 administration in both cases. By Day 2, ALP
expression decreased as compared to Day 1 for 10 and
50 lg/mL. There was no change in ALP expression from
Day 2 to Day 4 for 10 and 50 lg/mL although it remained
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lower than Day 1 for both concentrations. At Day 4,
administration of siGNAS1 at 100 lg/mL and siLamin at
10 lg/mL had higher ALP expression than administration
of siGNAS1 at 10 lg/mL. Cells administered siLamin at
10 lg/mL and siGNAS1 at 100 lg/mL had higher ALP
expression than no-scaffold/no-siGNAS1 controls.
Representative micro-CT imaging of bone in the
chambers showed differences in bone formation for the
three siRNA groups (siGNAS1, siPHD2, and siGNAS1-
siPHD2) from Day 7 to Day 70 (Fig. 8). Bone formation
was observed at the periosteum interface (bottom of the
chamber) as early as Day 7. By Day 21, there appeared to
be an increase in bone formation at the interface and into
the chamber in siPHD2-SFCS and siGNAS1-siPHD2-
SFCS. There was further filling of the chamber with bone
at Days 36 and 70 for all three conditions. Quantification of
the bone volume indicated no difference in the empty
chamber negative control with time and a decrease in bone
volume of bone graft-positive controls with time (Table 1).
There was also a difference in the bone volume between
bone graft and empty chambers at Days 7 and 21. There
was no change in bone mass density with time for bone
graft and empty chambers (Table 1).
H&E staining of empty chamber microsections showed
heterotopic bone formation within periosteum at the mus-
cle-periosteum interface by Day 21 (Fig. 9). Histologic
Movat’s pentachrome-stained microsections showed bone
formation in SFCS scaffolds with siGNAS1, siPHD2, and
siPHD2-siGNAS1 at Days 21 and 36 (Fig. 10).
At Day 7, there was no difference in bone volume
among the siRNA-embedded SFCS scaffolds (Fig. 11). At
Day 21, siPHD2-SFCS and siGNAS1-siPHD2-SFCS
Fig. 4 Cellular proliferation was
measured using MTT assay for
MSCs transfected with siGNAS1,
siPHD2, siGNAS1-siPHD2, and
no siRNA. MSC proliferation
decreased with the administration
of siRNA within 24 hours whereas
there was an increase in cell
number without any siRNA admin-
istration. Comparison among
groups with time shows differ-
ences: * = p\0.05, ** = p\0.01,
and *** = p \ 0.001 compared to
Day 4 in the same group; a = p \
0.05 and aa = p \ 0.01 compared
to GNAS1; b = p \ 0.05, bb =
p \ 0.01, and bbb = p \ 0.001
compared to no siRNA within the
respective time point. Values are
expressed as mean ± SEM.
Fig. 5 Collagen I expression was
determined for MSCs transfected
with siGNAS1, siPHD2, siGNAS1-
siPHD2, siLamin, and no siRNA
using Western blot. Maximal col-
lagen I expression was observed
at Day 2 in siGNAS1-treated
cells. Comparison among groups
with time shows differences: *** =
p \ 0.001 compared to Day 1;
## = p \ 0.01 compared to Day
4. Values are expressed as
mean ± SEM.
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tended to have higher bone volumes than SFCS and si-
GNAS1-SFCS. At Day 36, the maximal bone volume was
observed for siPHD2-SFCS and was higher than Day 7. By
Day 70, bone volume for siGNAS1-SFCS increased com-
pared to Days 7 and 21, that for siPHD2-SFCS increased
compared to Day 7, and that for siGNAS1-siPHD2-SFCS
Fig. 6 Osteopontin expression was determined for MSCs transfected
with siGNAS1, siPHD2, siGNAS1 and siPHD2, siLamin, and no
siRNA using Western blot. Osteopontin expression was maximal
within 24 hours of siGNAS1 administration and decreased with time
by Day 4, reaching the same expression level as siPHD2. The
expression of osteopontin remained low for siPHD2-administered
cells over the 4-day measurements. Comparison among groups with
time shows differences: * = p \ 0.05, ** = p \ 0.01, and *** =
p \ 0.001 compared to siGNAS1 within the respective time point;
aa = p \ 0.01 and aaa = p \ 0.001 compared to Day 1 siGNAS1;
b = p \ 0.05 compared to Day 2 siGNAS1. Values are expressed as
mean ± SEM.
Fig. 7 ALP assay was used to determine the effect of siGNAS1
concentrations at 10, 50, and 100 lg/mL and compared to siLamin
(10, 50, and 100 lg/mL), scaffold only (no siRNA), and no scaffold
(no siRNA) controls. The maximal ALP expression was observed for
10 and 50 lg/mL at Day 1, which decreased with time. The ALP
expression for 100 lg/mL increased from Day 1 to Day 4. Compar-
ison among groups shows differences: * = p \ 0.05, ** = p \ 0.01,
*** = p \ 0.001 compared to 10 lg/mL siGNAS1; aaa = p \
0.001 and aa = p \ 0.01 compared to 50 lg/mL GNAS1; b = p \
0.05 compared to scaffold only; $$ = p \ 0.01 and $ = p \ 0.05
compared to 100 lg/mL siGNAS1; @@ = p \ 0.01 compared to
10 lg/mL siLamin; ### = p \ 0.01 compared to Day 1 for 10 lg/
mL siGNAS1; ++ = p \ 0.01 and + = p \ 0.05 compared to Day
1 for 50 lg/mL siGNAS1. Values are expressed as mean ± SEM.
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increased compared to Days 7 and 36. There was no dif-
ference in bone mass density among the siRNA-SFCS
groups (Fig. 12).
Discussion
siRNA allows the regulation of multiple cellular pathways.
The Cbfa1 and HIF-1 pathways can be modulated to direct
bone formation via siGNAS1 and siPHD2, respectively.
We assessed the use of these siRNAs for modulating the
bone formation pathway to provide a tool for promoting
and directing the growth of functional bone for repair
and reconstructive surgery applications. We determined
(1) how the administration of siGNAS1 and siPHD2 in
MSCs affects cell proliferation and collagen, osteopontin,
and ALP expression; (2) how the dose of siGNAS1 affects
ALP expression in MSCs as a bone differentiation marker
and what concentration of siGNAS1 was needed for the in
vivo bone formation study; and (3) whether the two siRNAs
affect in vivo bone formation by measuring bone volume
and density with time.
There were several limitations to this study. First, while
we observed bone formation, the model provided no
mechanical loading apart from the mechanical simulation
from movement of the latissimus dorsi muscle. However,
mechanical loading affects the bone formation with growth
Fig. 8 Micro-CT imaging of
bone regeneration in pure SFCS
scaffolds, siGNAS1-SFCS, siPHD2-
SFCS, and siGNAS1-siPHD2-
SFCS scaffolds at Days 7, 21,
36, and 70 after implantation
shows bone formation in white.
Bone formation is observed at
the periosteum-chamber inter-
face as early as Day 21 in SFCS,
siPHD2-SFCS, and siGNAS1-
siPHD2-SFCS. Bone filled into
the chamber from Day 36 to Day
70 for siGNAS1-SFCS, siPHD2-
SFCS, and siGNAS1-siPHD2-SFCS.
Table 1. Bone volume and bone mass density of bone graft and empty chambers
Variable Day 7 Day 21 Day 36 Day 70
Bone volume (mm3)
Bone graft 1436.0 ± 185.3 1036.8 ± 246.0 531.7 ± 77.9*, 50.8*,,k
Empty 135.0 ± 129.4* 195.2 ± 178.0 2.9 ± 2.8§ 1.6
Bone density (mg/cm3)
Bone graft 628.0 ± 6.1 646.2 ± 17.1 667.7 ± 42.3 708.1
Empty 165.3 ± 65.4 212.7 ± 6.5 116.4 ± 45.0 177.2
Values are expressed as mean ± standard error of the mean; * p \ 0.0001, p \ 0.01, as compared to bone graft at Day 7; p \ 0.001, as
compared to bone graft at Day 21; §p \ 0.0001, kp \ 0.01, as compared to bone graft at Day 36.
Fig. 9 H&E staining of a 4-lm section of tissue harvested at Day 21
shows heterotopic bone formation at the muscle-periosteum interface
with mineralizing bone in reddish-pink surrounding the newly
forming marrow spaces in the middle.
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Fig. 10 Movat’s pentachrome staining of 4-lm sections of tissue
harvested at Days 21 and 36 shows mineralizing bone in deep
yellowish-brown and mineralizing silk fibroin fibrils in pinkish-red.
At Day 36, black india ink perfusion shows the vasculature in black
for siGNAS1, siPHD2, and siGNAS1-siPHD2.
ββ
αα
Fig. 11 Bone volume was plotted
against time to assess bone for-
mation for SFCS scaffolds
modified with siGNAS1, siPHD2,
and siGNAS1-siPHD2. There was
an overall increase in bone vol-
ume from Day 7 to Day 70 for
siRNA-embedded scaffolds. For
the siGNAS1 group, *** =
p \ 0.0001 compared to Day 70;
for the siPHD2 group, aa = p \
0.01 compared to Day 36 and
bb = p \ 0.01 compared to Day
70; for the siGNAS1-siPHD2 group,
## = p \ 0.01 compared to Day
70. Values are expressed as
mean ± SEM.
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factor signaling in a clinical setting [9]. This type of pre-
fabricated bone with no mechanical loading could have
clinical applications. Such constructs could be moved as a
bone tissue flap with the vascular supply from latissimus
dorsi to a mechanically loaded defect site where the vas-
cular supply could be connected but would have to be
supported with metallic plates and screws initially until this
prefabricated bone remodeled to specifications of the
mechanical loading at the defect repair site. Second, we
had only two experimental samples at Day 70 although we
noted an increase in bone volume at Day 70 compared to
Day 7. Third, siPHD2 and siGNAS1 both guide bone for-
mation via complex and different intercellular mechanisms
that were not explored in this study. Fourth, the overall
concentration of the loaded siRNA in the SFCS scaffold
and the rate of release of siRNA relative to the cells
migrating into the scaffold, degradation of scaffold, dif-
ferentiation of cells into osteogenic phenotype, and
remodeling of new tissue in the sheep model need further
investigation. Fifth, with the in vivo sheep model, no cells
were seeded in the scaffold before implantation and the cell
source for in vivo bone formation was limited to the
periosteum. Since the vascular supply to the periosteum
and the newly forming bone in the scaffold are from the
latissimus dorsi muscle, cells would migrate in with the
nutrient supply from the vasculature. Although it is well
established that the cambium layer of the periosteum pro-
vides bone precursor cells, other cells that vascularize the
scaffold may either migrate from the periosteum connec-
tive tissue or from the adjacent muscle.
We found osteogenic differentiation of MSCs can be
mediated via siGNAS1 as indicated by increased expression
of collagen I, osteopontin, and ALP. The administration of
both siGNAS1 and siPHD2 slowed the proliferation of cells
as compared to no-siRNA controls. Cellular proliferation
was decreased by the presence of siRNA probably due to
guidance toward the bone differentiation pathway. The cell
cycle arrest in MSCs has been observed by others as the cells
are directed toward a differentiation pathway [14]. In this
study, collagen I expression was maximal at Day 2 after
siGNAS1 administration in MSCs. Collagen I is the primary
component of the bone extracellular matrix and its expression
is regulated by the Cbfa1 transcriptional regulator [2, 5].
siGNAS1 promoted the expression of the proteins in the
Cbfa1 pathway, while there was no effect of siPHD2 on the
collagen I expression. Osteopontin, a phosphorylated
sialoprotein, is found in the bone extracellular matrix [12].
Osteopontin expression would be expected to increase as a
marker for the osteogenic phenotype as observed in this
study within 1 day of exposure to siGNAS1 in MSCs.
Osteogenic differentiation of MSCs marked by increase in
Cbfa1 expression due to administration of antisense Gsa,
which simulates inactivation of the GNAS1 gene similar to
siRNA administration, has been studied [7]. Additionally,
coadministration of siRNAs against GNAS1 and BMP2
reportedly accelerates the differentiation of human adipose
tissue-derived stem cells toward osteogenic lineage [10].
siGNAS1 concentration affected ALP expression of
MSCs. We performed the siGNAS1 dose assessment to
determine the siGNAS1 concentration needed for the in
vivo study. Lower concentrations of siGNAS1 exhibited
higher ALP at Day 1, and as the siRNA depleted by Days 2
and 4, the ALP was reduced. While 10 and 50 lg/mL
siGNAS1 resulted in maximal ALP expression after Day 1,
the ALP expression decreased considerably for 10 lg/mL
and intermediate effects were observed for 50 lg/mL as
compared to 10 and 100 lg/mL. For the higher-concentration
of siGNAS1, maximal ALP expression was not observed
Fig. 12 Bone mass density was
plotted against time for SFCS
scaffolds modified with siGNAS1,
siPHD2, and siGNAS1-siPHD2.
There was no difference in bone
mass density among the groups.
Values are expressed as mean ±
SEM.
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until Day 4, probably due to the effect of siRNA admin-
istration on cellular proliferation since the concentration
values were normalized with overall cell number. The
effect of siRNA in the cellular system on the cellular
proliferation may have dominated the effect of siGNAS1
on the bone differentiation phenotype at short time points
for 100 lg/mL. ALP detected at Day 1 was the lowest
compared to 10 and 50 lg/mL, and as the cells proliferated
by Day 4 and the siGNAS1 was utilized by the cells, the
overall ALP expression increased for 100 lg/mL. Since the
siGNAS1 targeted cellular proliferation and differentiation
into an osteogenic phenotype in MSCs, the dose-dependent
effects evident in this study were a function of the pro-
liferation/differentiation balance that the cells try to achieve
with siRNA administration to their system. Increased ALP
activity, collagen I expression, and osteocalcin expression
with increased in vivo bone formation have also been
reported for Cbfa1 adenovirus-transfected MSCs [4].
In vivo data suggested an overall increase in bone volume
from Day 7 to Day 70 in siGNAS1, siPHD2, and siGNAS1-
siPHD2. At Day 21, siGNAS1-administered cells had a
lower volume of bone, which increased by Day 70. An
increase in bone volume was observed for siGNAS1,
siPHD2, and siGNAS1-siPHD2 from Day 7 to Day 70. No
change in bone density for any of the conditions indi-
cated consistent bone density was maintained in the newly
forming bone in the SFCS scaffolds with time up to
70 days.
The in vitro and in vivo effects of siPHD2 on bone for-
mation were different. The sequence of siPHD2 used has
been well tested in our laboratory to show it results in
downregulation of PHD2 and upregulation of angiogenic
factors such as iNOS [3]. It also promotes vacuole formation
in endothelial cells at short time points (within 24 hours) and
microvascular network formation by 96 hours. In this study,
in vivo bone formation was aided by cells incoming from the
periosteum and the adjacent latissimus dorsi muscle pro-
viding the vascular supply [16] to the periosteum. Thus,
siPHD2 had the opportunity to act on other cells besides the
bone precursors, although the siPHD2-driven vascular phe-
notype may support the regeneration of bone by supporting
the nutrient supply to the growing bone.
The silencing RNA mechanism allowed us to control the
fate of cell proliferation and differentiation by targeting the
expression of multiple proteins via a single siRNA admin-
istration. Since siRNA affects the proliferative capacity of
cells, for bone formation of critical sizes, it is important to
consider the type of cells with respect to the type of siRNA,
time of siRNA introduction, amount or concentration of
siRNA with respect to the number of cells in the system, and
sustained release of needed amount with time, so as to not to
promote premature differentiation of cells without adequate
proliferation to fill or repair a defect.
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